EXHIBIT 99.1

For more information contact:

Alex Edwards
813-264-2241



FOR IMMEDIATE RELEASE


   Nanobac Pharmaceuticals, Inc. announces the Election of Two Outside Board
                                    Members

TAMPA, Fla. (February 2, 2004)-- Nanobac Pharmaceuticals, Inc. (OTCPK:NNBP)
("Nanobac" or "The Company").

     John Stanton, Chairman of the Board, announces the election of Dr. Jan
Egberts and Dr. Stephan Rechtschaffen as independent directors of the Company.

     "In the election of these directors, the company has sought to bring a
diverse group of executives to the leadership of the company," said Mr. Stanton.
"Both of these directors bring unique corporate and medical experiences that
will be integral in guiding the company in the successful execution of its
business plan."

     Dr. Jan Egberts received his medical degree from Erasmus University Medical
School, Rottendam, the Netherlands in 1985, with medical studies at John Hopkins
and Harvard medical schools. He received his MBA from Stanford Graduate School
of Business in 1989.

     For the past three years he has served as Chairman and Managing Director of
Molnlycke Healthcare, Inc. in Newtown, PA.

     Prior to Molnlycke Dr. Egberts served as Vice President, Business and
Market Development world wide for Johnson & Johnson, New Brunswick, NJ. He was a
member of the Global Management Board of $1.3 Billion Johnson & Johnson medical
franchise with seven divisions. He was responsible for licensing/acquisitions,
equity investment and patent management.

     Prior to Johnson & Johnson Dr. Egberts was a Senior Marketing Director with
Merck & Company in West Point, PA; Partner Egberts & Company, Amsterdam;
Engagement Manager, McKinsey & Company in New York, Dusseldorf, London and
Amsterdam; Project Manager, Cancer Biotechnology Research and Development
Organon / Bionetics Research, Inc.

     Dr. Stephan Rechtschaffen received his medical degree in 1973 from New York
Medical College in New York City. His residency was at Harkness Community
Hospital in San Francisco. He co-founded Omega Institute in 1977 and is the CEO
and Chair of the Board. He was the developer and director of Foxhollow Wellness
Spa in Lenox, MA from 1987 - 1989, and director of the Rhinebeck Health Center
in Rhinebeck, NY, from 1983 - 1989.

     Dr. Rechtschaffen is a nationally recognized holistic physician who
lectures on health, wellness, nutrition, longevity and time. He has organized
symposia and educational programs throughout the country.

     Dr. Rechtschaffen is the author of: TimeShifting; Creating More Time to
Enjoy Your Life, 1996, published in the United States by Doubleday, and in
England, Europe, Japan and Australia by Random House. He is co-author of
Vitality and Wellness, 1999, published by Dell.



     Dr. Rechtschaffen has presented these concepts in TimeShifting, Health and
Wellness, and in Organizational Management workshops at many corporations:
Citibank, Avon, Aveda, ConEdison, IBM, Dana Farber Cancer Institute, Kaiser
Permanente, Mercedes-Benz, Natural Health Business Strategies, Preventative
Medicine Research, Salon Systems and Young Presidents Organization, and others.

     Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida, U.S.A.
For more information, please visit our website at www.nanobaclabs.com or contact
us at info@nanobaclabs.com.

     Investors are cautioned that certain statements contained in this document
as well as some statements in periodic press releases and some oral statements
of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 (the
"Act"). Forward-Looking statements include statements which are predictive in
nature, which depend upon or refer to future events or conditions, which include
words such as "believes," "anticipates," "intends," "plans," "expects," and
similar expressions. In addition, any statements concerning future financial
performance (including future revenues, earnings or growth rates), ongoing
business strategies or prospects, and possible future Nanobac Pharmaceuticals,
Inc. actions, which may be provided by management, are also forward-looking
statements as defined by the Act. Forward-Looking statements involve known and
unknown risks, uncertainties, and other factors which might cause the actual
results, performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied by such
forward-looking statements and to vary significantly from reporting period to
reporting period. Although management believes that the assumptions will, in
fact, prove to be correct or that actual future results will not be different
from the expectations expressed in this report, these statements are not
guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no
specific intention to update these statements.


###